1
|
Perontsis S, Geromichalos GD, Pekou A, Hatzidimitriou AG, Pantazaki A, Fylaktakidou KC, Psomas G. Structure and biological evaluation of pyridine-2-carboxamidine copper(II) complex resulting from N′-(4-nitrophenylsulfonyloxy)2-pyridine-carboxamidoxime. J Inorg Biochem 2020; 208:111085. [DOI: 10.1016/j.jinorgbio.2020.111085] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2020] [Revised: 03/30/2020] [Accepted: 04/08/2020] [Indexed: 10/24/2022]
|
2
|
Berger O, Ortial S, Wein S, Denoyelle S, Bressolle F, Durand T, Escale R, Vial HJ, Vo-Hoang Y. Evaluation of amidoxime derivatives as prodrug candidates of potent bis-cationic antimalarials. Bioorg Med Chem Lett 2019; 29:2203-2207. [PMID: 31255483 DOI: 10.1016/j.bmcl.2019.06.045] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2019] [Revised: 06/18/2019] [Accepted: 06/22/2019] [Indexed: 01/27/2023]
Abstract
Plasmodium falciparum is responsible for most of the cases of malaria and its resistance to established antimalarial drugs is a major issue. Thus, new chemotherapies are needed to fight the emerging multi-drug resistance of P. falciparum malaria, like choline analogues targeting plasmodial phospholipidic metabolism. Here we describe the synthesis of amidoxime derivatives as prodrug candidates of reverse-benzamidines and hybrid compounds able to mimic choline, as well as the design of a new series of asymmetrical bis-cationic compounds. Bioconversion studies were conducted on amidoximes in asymmetrical series and showed that amidoxime prodrug strategy could be applied on C-alkylamidine moieties, like benzamidines and that N-substituents did not alter the bioconversion of amidoximes. The antimalarial activity of the three series of compounds was evaluated in vitro against P. falciparum and in vivo against P. vinckei petteri in mice.
Collapse
Affiliation(s)
- Olivier Berger
- Institut des Biomolecules Max Mousseron, UMR 5247, Université de Montpellier, CNRS, ENSCM, Faculté des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier, France
| | - Stéphanie Ortial
- Institut des Biomolecules Max Mousseron, UMR 5247, Université de Montpellier, CNRS, ENSCM, Faculté des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier, France
| | - Sharon Wein
- Dynamique Moléculaire des Interactions Membranaires Normales et Pathologiques, Université de Montpellier, UMR 5235 CNRS, Place Eugène Bataillon, 34095 Montpellier, France
| | - Séverine Denoyelle
- Institut des Biomolecules Max Mousseron, UMR 5247, Université de Montpellier, CNRS, ENSCM, Faculté des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier, France
| | - Françoise Bressolle
- Pharmacocinetique Clinique, EA4215, Faculté des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier, France
| | - Thierry Durand
- Institut des Biomolecules Max Mousseron, UMR 5247, Université de Montpellier, CNRS, ENSCM, Faculté des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier, France
| | - Roger Escale
- Institut des Biomolecules Max Mousseron, UMR 5247, Université de Montpellier, CNRS, ENSCM, Faculté des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier, France
| | - Henri J Vial
- Dynamique Moléculaire des Interactions Membranaires Normales et Pathologiques, Université de Montpellier, UMR 5235 CNRS, Place Eugène Bataillon, 34095 Montpellier, France
| | - Yen Vo-Hoang
- Institut des Biomolecules Max Mousseron, UMR 5247, Université de Montpellier, CNRS, ENSCM, Faculté des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier, France.
| |
Collapse
|
3
|
Papastergiou A, Perontsis S, Gritzapis P, Koumbis AE, Koffa M, Psomas G, Fylaktakidou KC. Evaluation of O-alkyl and aryl sulfonyl aromatic and heteroaromatic amidoximes as novel potent DNA photo-cleavers. Photochem Photobiol Sci 2016; 15:351-60. [DOI: 10.1039/c5pp00439j] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
O-Alkyl and aryl p-pyridine sulfonyl amidoxime derivatives are effective novel DNA photo-cleavers, generating highly efficient sulfonyloxyl radicals, able to cause a high ratio of single to double strand nicks.
Collapse
Affiliation(s)
- A. Papastergiou
- Laboratory of Organic
- Bioorganic and Natural Product Chemistry
- Molecular Biology and Genetics Department
- Democritus University of Thrace
- Alexandroupolis
| | - S. Perontsis
- Laboratory of Inorganic Chemistry
- Chemistry Department
- Aristotle University of Thessaloniki
- Thessaloniki
- Greece
| | - P. Gritzapis
- Laboratory of Organic
- Bioorganic and Natural Product Chemistry
- Molecular Biology and Genetics Department
- Democritus University of Thrace
- Alexandroupolis
| | - A. E. Koumbis
- Laboratory of Organic Chemistry
- Chemistry Department
- Aristotle University of Thessaloniki
- Thessaloniki
- Greece
| | - M. Koffa
- Laboratory of Cellular Biology and Cell Cycle
- Molecular Biology and Genetics Department
- Democritus University of Thrace
- Alexandroupolis
- Greece
| | - G. Psomas
- Laboratory of Inorganic Chemistry
- Chemistry Department
- Aristotle University of Thessaloniki
- Thessaloniki
- Greece
| | - K. C. Fylaktakidou
- Laboratory of Organic
- Bioorganic and Natural Product Chemistry
- Molecular Biology and Genetics Department
- Democritus University of Thrace
- Alexandroupolis
| |
Collapse
|
4
|
Degardin M, Wein S, Duckert JF, Maynadier M, Guy A, Durand T, Escale R, Vial H, Vo-Hoang Y. Development of the first oral bioprecursors of bis-alkylguanidine antimalarial drugs. ChemMedChem 2014; 9:300-4. [PMID: 24403182 DOI: 10.1002/cmdc.201300419] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2013] [Indexed: 11/07/2022]
Abstract
Plasmodium falciparum is responsible of the most severe form of malaria, and new targets and novel chemotherapeutic scaffolds are needed to fight emerging multidrug-resistant strains of this parasite. Bis-alkylguanidines have been designed to mimic choline, resulting in the inhibition of plasmodial de novo phosphatidylcholine biosynthesis. Despite potent in vitro antiplasmodial and in vivo antimalarial activities, a major drawback of these compounds for further clinical development is their low oral bioavailability. To solve this issue, various modulations were performed on bis-alkylguanidines. The introduction of N-disubstituents on the guanidino motif improved both in vitro and in vivo activities. On the other hand, in vivo pharmacological evaluation in a mouse model showed that the N-hydroxylated derivatives constitute the first oral bioprecursors in bis-alkylguanidine series. This study paves the way for bis-alkylguanidine-based oral antimalarial agents targeting plasmodial phospholipid metabolism.
Collapse
Affiliation(s)
- Mélissa Degardin
- UMR 5247 CNRS-UMI-UMII-ENSCM, Institut des Biomolecules Max Mousseron (IBMM), Faculté des Sciences Pharmaceutiques et Biologiques, Université de Montpellier I/II, 15 Avenue Charles Flahault, 34093 Montpellier (France)
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Biamonte MA, Wanner J, Le Roch KG. Recent advances in malaria drug discovery. Bioorg Med Chem Lett 2013; 23:2829-43. [PMID: 23587422 PMCID: PMC3762334 DOI: 10.1016/j.bmcl.2013.03.067] [Citation(s) in RCA: 129] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2013] [Revised: 03/11/2013] [Accepted: 03/20/2013] [Indexed: 01/18/2023]
Abstract
This digest covers some of the most relevant progress in malaria drug discovery published between 2010 and 2012. There is an urgent need to develop new antimalarial drugs. Such drugs can target the blood stage of the disease to alleviate the symptoms, the liver stage to prevent relapses, and the transmission stage to protect other humans. The pipeline for the blood stage is becoming robust, but this should not be a source of complacency, as the current therapies set a high standard. Drug discovery efforts directed towards the liver and transmission stages are in their infancy but are receiving increasing attention as targeting these stages could be instrumental in eradicating malaria.
Collapse
Affiliation(s)
- Marco A Biamonte
- Drug Discovery for Tropical Diseases, Suite 230, San Diego, CA 92121, USA.
| | | | | |
Collapse
|